Skip to main content

Advertisement

SpringerLink
Log in

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization

  • Cornea
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the short- and long-term in vivo safety and efficacy of topical bevacizumab (Avastin) application for treatment of corneal neovascularization secondary to a variety of corneal diseases.

Methods

Thirty eyes of 27 patients with progressive corneal neovascularisation (not responding to conventional anti-inflammatory treatment) due to different underlying corneal diseases received topical bevacizumab (Avastin) eye drops (5 mg/ml Bevacizumab) for 0.5–12 months (five times/day on average). At each visit, a routine Snellen visual acuity assessment was performed, followed by ophthalmic examination including fluorescein staining. Changes of corneal neovascularization and vessel diameter were assessed using morphometry of standardized digital corneal photographs.

Results

Five patients (five eyes) developed new corneal epithelial defects during topical bevacizumab treatment. In 22 patients, no new epithelial defects were observed. None of the 27 patients complained about any drug-related ocular or systemic adverse events during follow-up. No allergic reactions were observed.

Corneal photographs of 21 eyes (19 patients) could be assessed. The mean reduction in vascularized area during treatment was 61%. The mean reduction in vessel diameter under topical Avastin therapy was 24%.

Conclusions

Off-label topical bevacizumab therapy against corneal neovascularization secondary to different corneal diseases was generally well-tolerated for up to 12 months. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization, and lead to a reduction of the vessel diameter. Our results suggest that off-label use of Bevacizumab eye drops is a relatively safe and well-tolerated option for the treatment of corneal neovascularization. Care should be taken in patients with epithelial defects and neurotrophic keratopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249, doi:10.1097/00055735-200108000-00002

    Article  PubMed  CAS  Google Scholar 

  2. Bock F, Koenig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336–344, doi:10.1007/s00347-007-1512-2

    Article  PubMed  CAS  Google Scholar 

  3. Cursiefen C, Chen L, Saint-Geniez M et al (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 103:11405–11410, doi:10.1073/pnas.0506112103

    Article  PubMed  CAS  Google Scholar 

  4. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257, doi:10.1038/35025220

    Article  PubMed  CAS  Google Scholar 

  5. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487, doi:10.1056/NEJM199412013312203

    Article  PubMed  CAS  Google Scholar 

  6. Yoeruek E, Spitzer MS, Tatar O et al (2007) Safety profile of Bevacizumab on cultured human corneal cells. Cornea 26:977–982, doi:10.1097/ICO.0b013e3180de1d0a

    Article  PubMed  Google Scholar 

  7. Bock F, Koenig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281–284, doi:10.1007/s00417-007-0684-4

    Article  PubMed  CAS  Google Scholar 

  8. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical Bevacizumab on corneal neovascularization. Ophthalmology 115:e33–e38, doi:10.1016/j.ophtha.2008.02.013

    Article  PubMed  Google Scholar 

  9. Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514–2522

    PubMed  CAS  Google Scholar 

  10. Cursiefen C, Rummelt C, Küchle M (2000) Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 19:526–533. doi:10.1097/00003226-200007000-00025

    Article  PubMed  CAS  Google Scholar 

  11. Irigoyen JP, Moñoz-Cánoves P, Montero L et al (1999) The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56:104–132, doi:10.1007/PL00000615

    Article  PubMed  CAS  Google Scholar 

  12. Blasi F (1999) Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 82:298–304

    PubMed  CAS  Google Scholar 

  13. Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545–2552, doi:10.1167/iovs.06-0570

    Article  PubMed  Google Scholar 

  14. Fernando NH, Hurwitz HI (2004) Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9:11–18, doi:10.1634/theoncologist.9-suppl_1-11

    Article  PubMed  CAS  Google Scholar 

  15. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372, doi:10.1016/j.ophtha.2005.11.019

    Article  PubMed  Google Scholar 

  16. Krum JM, Rosenstein JM (2004) New roles for VEGF in nervous tissue: beyond blood vessels. Exp Neurol 187:246–253, doi:10.1016/j.expneurol.2004.01.022

    Article  PubMed  Google Scholar 

  17. Soubrane G, Jerdan J, Karpouzas I et al (1990) Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci 31:323–333

    PubMed  CAS  Google Scholar 

  18. Bock F, Onderka J, Hos D, Horn F, Martus P, Cursiefen C (2008) Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 87:462–470, doi:10.1016/j.exer.2008.08.007

    Article  PubMed  CAS  Google Scholar 

  19. Cursiefen C, Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87:101–106, doi:10.1136/bjo.87.1.101

    Article  PubMed  CAS  Google Scholar 

  20. Sadrai Z, Dastjerdi MH, Saban DR, Dana R (2008) Corneal penetration of topical bevacizumab (Avastin). ARVO poster, 2008.

  21. Cursiefen C, Cao J, Chen L et al (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45(8):2666–2673, doi:10.1167/iovs.03-1380

    Article  PubMed  Google Scholar 

  22. Bachmann BO, Bock F, Wiegand SJ et al (2008) Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 126(1):71–77, doi:10.1001/archopht.126.1.71

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany

    Yanyan Koenig, Felix Bock, Folkert Horn, Friedrich Kruse & Claus Cursiefen

  2. University Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany

    Katja Straub

Authors
  1. Yanyan Koenig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felix Bock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Folkert Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Friedrich Kruse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katja Straub
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claus Cursiefen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claus Cursiefen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koenig, Y., Bock, F., Horn, F. et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247, 1375–1382 (2009). https://doi.org/10.1007/s00417-009-1099-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-009-1099-1

Keywords

Search

Navigation